Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Acquires $32,760.00 in Stock
Greenwich LifeSciences, Inc. CEO Snehal Patel acquired 3,600 shares of the company's stock at $9.10 per share, totaling $32,760. Following this purchase, Patel now owns 5,561,602 shares valued at approximately $50.6 million, marking a 0.06% increase in ownership. The stock recently traded at $9.62, with a 12-month range of $8.06 to $18.75. Analyst HC Wainwright maintains a "buy" rating with a $38 price target. Institutional investors have also increased their stakes in the company, which focuses on developing cancer immunotherapies.
Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel purchased 3,600 shares of the firm's stock in a transaction on Monday, April 7th. The stock was bought at an average price of $9.10 per share, for a total transaction of $32,760.00. Following the acquisition, the chief executive officer now owns 5,561,602 shares in the company, valued at $50,610,578.20. The trade was a 0.06 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Get Greenwich LifeSciences alerts:
Snehal Patel also recently made the following trade(s):
- On Friday, April 4th, Snehal Patel bought 5,500 shares of Greenwich LifeSciences stock. The stock was purchased at an average price of $8.73 per share, for a total transaction of $48,015.00.
- On Friday, January 10th, Snehal Patel purchased 2,500 shares of Greenwich LifeSciences stock. The shares were purchased at an average price of $12.51 per share, with a total value of $31,275.00.
Greenwich LifeSciences Stock Up 0.3 %
Shares of Greenwich LifeSciences stock traded up $0.03 during trading hours on Tuesday, hitting $9.62. 13,852 shares of the company's stock traded hands, compared to its average volume of 40,189. Greenwich LifeSciences, Inc. has a twelve month low of $8.06 and a twelve month high of $18.75. The stock has a 50 day simple moving average of $11.65 and a 200-day simple moving average of $12.75. The company has a market cap of $126.39 million, a PE ratio of -12.02 and a beta of 1.76.
Analyst Ratings Changes
Separately, HC Wainwright reaffirmed a "buy" rating and set a $38.00 price target on shares of Greenwich LifeSciences in a research report on Tuesday, February 11th.
Read Our Latest Analysis on GLSI
Institutional Trading of Greenwich LifeSciences
Institutional investors and hedge funds have recently bought and sold shares of the company. Wells Fargo & Company MN raised its holdings in shares of Greenwich LifeSciences by 54.8% during the fourth quarter. Wells Fargo & Company MN now owns 2,847 shares of the company's stock worth $32,000 after purchasing an additional 1,008 shares during the period. Brown Brothers Harriman & Co. acquired a new stake in Greenwich LifeSciences during the fourth quarter worth about $45,000. JPMorgan Chase & Co. lifted its holdings in Greenwich LifeSciences by 172.0% in the fourth quarter. JPMorgan Chase & Co. now owns 7,061 shares of the company's stock worth $79,000 after acquiring an additional 4,465 shares during the last quarter. Bank of America Corp DE boosted its stake in Greenwich LifeSciences by 22.3% in the fourth quarter. Bank of America Corp DE now owns 7,262 shares of the company's stock valued at $82,000 after acquiring an additional 1,322 shares during the period. Finally, Barclays PLC grew its holdings in shares of Greenwich LifeSciences by 12.7% during the fourth quarter. Barclays PLC now owns 9,648 shares of the company's stock valued at $108,000 after purchasing an additional 1,088 shares during the last quarter. Institutional investors and hedge funds own 4.16% of the company's stock.
About Greenwich LifeSciences
(Get Free Report)Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.
Further Reading
- Five stocks we like better than Greenwich LifeSciences
- What is a Low P/E Ratio and What Does it Tell Investors?
- PayPal Stock: Too Cheap to Ignore, Too Strong to Miss
- What Are Dividend Achievers? An Introduction
- Progress Software: Making Progress Driven by the AI Revolution
- What is the Dow Jones Industrial Average (DJIA)?
- Intel-Taiwan Semiconductor Alliance Fuels Turnaround Hopes
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Greenwich LifeSciences Right Now?
Before you consider Greenwich LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Greenwich LifeSciences wasn't on the list.
While Greenwich LifeSciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
